We are dedicated to developing and delivering first-in-class therapies for patients facing devastating neurodegenerative diseases, hematologic malignancies, and high-consequence viral infections.

Founded and supported by world-renowned scientists, including two Nobel laureates, we has pioneered a cutting-edge drug discovery platform focused on high-value therapeutic targets, including the chemokine receptor CXCR4 and viral proteases.

By developing innovative small-molecule therapies that target key disease mechanisms, we aim to address critical gaps in current standards of care where existing treatments are limited by drug resistance, safety concerns, or inadequate efficacy.